Last reviewed · How we verify

Avexa — Portfolio Competitive Intelligence Brief

Avexa pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
3TC 3TC marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase; hepatitis B polymerase Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 shared drug class
  2. Asan Medical Center · 1 shared drug class
  3. Bristol-Myers Squibb · 1 shared drug class
  4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
  5. Dong-A ST Co., Ltd. · 1 shared drug class
  6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
  7. French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
  8. ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Avexa:

Cite this brief

Drug Landscape (2026). Avexa — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/avexa. Accessed 2026-05-13.

Related